Moderna president hopeful that US can achieve herd immunity by mid-year
Dr. Stephen Hoge, president of American biotechnolgy company Moderna, said he's hopeful that vaccines can help the U.S. population achieve herd immunity against the novel coronavirus by mid-year.
"It really depends what you think herd immunity needs to be. But if you assume 50 to 70% of the population, then we're working hard ourselves and the other manufacturers to make sure that's a possibility really in the late spring, early summer," Hoge told ABC News chief anchor George Stephanopoulos in an interview Monday on "Good Morning America."
"It's ultimately going to depend upon the delivery of those vaccines, and so that's something that the states and the health care providers in this country are ultimately leading the way on as well as Americans deciding they want to receive that vaccine," he added. But we're optimistic that by the middle of the year, we'll be able to achieve those sorts of numbers."
Moderna is ramping up production of its COVID-19 vaccine and is working to clear any "bottlenecks" in the supply chain, according to Hoge.
"At this point, a lot of the logistical bottlenecks that we're running into are problems we can solve on our own," he noted. "We're in good shape."
Hoge, who was a resident physician in New York City, said data currently shows that existing vaccines are still effective against all emerging strains of the virus. But the variant first identified in South Africa "is of some concern because it looks like it could hide from the vaccine a little better than others," he said.
"So our approach in Moderna is going to be to develop a booster vaccine so that if the South African variant or any other variant becomes a concern, we'll be able to offer a way to identify that, prevent it from hiding from the vaccine," he said.